Progressive familial intrahepatic cholestasis

The PBS subsidises odevixibat for patients with progressive familial intrahepatic cholestasis (PFIC).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with odevixibat under the National Health Act 1953, section 85 for patients with PFIC.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing odevixibat.

Treatment specifics

To be eligible for PBS-subsidised treatment with odevixibat, patients diagnosed under the age of 18 must be treated by either a:

  • gastroenterologist experienced in the management of PFIC
  • hepatologist experienced in the management of PFIC.

Patients diagnosed over the age of 18 must be treated by a specialist hepatologist experienced in the management of PFIC.

Authority applications

Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for initial authority approval to prescribe PBS-subsidised odevixibat to treat PFIC can be made:

All written applications must include:

Applying for continuing, recommencement or dose modification

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Applications for continuing, recommencement or dose modification authority approval to prescribe PBS-subsidised odevixibat to treat PFIC can be made:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 January 2026.
QC 83515